Status:

UNKNOWN

Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza Vaccines

Lead Sponsor:

Probiomics Ltd

Conditions:

Influenza

Eligibility:

All Genders

18-49 years

Phase:

PHASE1

PHASE2

Brief Summary

This project aims to test the hypothesis that oral consumption of a specific strain of the probiotic bacterium Lactobacillus fermentum (trademarked PCC®) is able to significantly enhance the immune re...

Eligibility Criteria

Inclusion

  • Persons must be adult men and women aged 18-49 years (have not reached 50th birthday).
  • Persons must be able and willing to provide informed consent.
  • Persons must be willing to receive the influenza vaccine (Fluvax®) given as an intramuscular injection.
  • Persons must be willing to consume one gelatin capsule per day containing either probiotic bacteria or placebo (inactive substance) for the duration (42 days) of the study.
  • Persons must be willing to provide blood specimens, each of 10 ml, collected by venepuncture.
  • Persons must be willing to notify study personnel of a range of health effects by questionnaire.

Exclusion

  • Any health condition for which the influenza vaccine is not recommended including: chronic diseases of the pulmonary or cardiovascular systems (including asthma); chronic metabolic diseases (including diabetes); renal dysfunction; hemoglobinopathies; immune deficiency diseases (including HIV infection) or on-going immunosuppressive therapy.
  • Currently pregnant; nursing mothers; or planning a pregnancy within one month of vaccination.
  • Allergy to latex, egg, or egg protein, or the antibiotics neomycin or polymyxin.
  • A prior serious reaction to a vaccine, or have had Guillain-Barre syndrome.
  • Received an influenza vaccine in the past.
  • Received any other vaccine within one month prior to enrolment
  • Are participating in another research study involving any study medication

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

End Date :

January 1 2007

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT00294788

Start Date

March 1 2006

End Date

January 1 2007

Last Update

January 9 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Good Health Solutions

Sydney, New South Wales, Australia, 2000